BIAF bioAffinity Technologies, Inc.

NEUTRAL Impact: 3/10 8-K
Horizon weeks Filed Mar 3, 2026 Processed 3mo ago SEC 0001493152-26-008723
8-K context-dependent: Items 8.01
Final — all horizons settled through T+60d
BIAF ▲ +60.19% at T+60d
NEUTRAL call ✓ call won +60.19% · α vs SPY +50.11% · entry $1.03 → $1.65
Last close $1.60 (close Jun 8) · +55.34% from $1.03 entry
Entry anchored
Mar 3, 03:35 PM ET
via Databento tick
T+1d
0.00%
call 0.00% · α +0.57%
$1.03
settled 3mo ago
T+5d
+9.71%
call +9.71% · α +11.04%
$1.13
settled 3mo ago
T+20d
+286.41%
call +286.41% · α +290.82%
$3.98
settled 2mo ago
T+60d
+60.19%
call +60.19% · α +50.11%
$1.65
settled 13d ago

Price Chart

Loading chart...

Executive Summary

BioAffinity Technologies, Inc. announced the presentation of a scientific poster at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2026 annual meeting, detailing research on its diagnostic platform for identifying optimal therapies for asthma and COPD patients. The research demonstrates the technology's ability to identify drug antibody receptors in sputum for leading asthma therapies.

Actionable Insight

Monitor future clinical trial results and regulatory developments for the asthma diagnostic platform, as successful validation could expand the company's market beyond lung cancer diagnostics.

Key Facts

  • Presented a poster titled 'Sputum as a Diagnostic Tool for the Treatment of Asthma' at the AAAAI 2026 annual meeting.
  • Research shows the company's diagnostic platform can identify antibody drug receptors in sputum for dupilumab and benralizumab, two leading asthma therapies.
  • The technology aims to assist physicians in matching asthma and COPD patients with effective therapies and monitoring inflammatory changes over time.
  • The platform is already used in the company's commercial test, CyPath® Lung, for early detection of lung cancer.

Financial Impact

No financial figures disclosed in the filing.

Risk Factors

  • The research is still in the early stages and may not lead to a commercially viable product.
  • The company faces competition from other diagnostic firms developing similar technologies.
  • The company's small market cap ($1M) indicates high financial risk and potential volatility.

Market Snapshot

Exchange
Nasdaq

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-008723
Exhibit: ex99-1.htm0001493152-26-008723
Document: 0001493152-26-008723-index-headers.html0001493152-26-008723
Document: 0001493152-26-008723-index.html0001493152-26-008723
Document: 0001493152-26-008723.txt0001493152-26-008723
2 reports for BIAF
Performance horizon
Filters
Rows
Reports for BIAF — sortable, filterable
Type Now
Mar 3, 2026
14w ago
8-K
NEUTRAL ★ 3/10
$1.03 $1.65▲ +60.19%▲ +50.11%$1.60 (+55.34%)
Feb 25, 2026
14w ago
8-K
NEUTRAL ★ 4/10
$1.09 $1.66▲ +52.29%▲ +45.34%$1.60 (+46.79%)
Showing 2 of 2

US Market Status

Market Closed — Opens in 8h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access